Mirsaeidi Mehdi, Barletta Pamela, Glassberg Marilyn K
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL, United States.
Front Med (Lausanne). 2019 Oct 31;6:248. doi: 10.3389/fmed.2019.00248. eCollection 2019.
A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.
系统性硬化症（SSc）患者的一个亚组会发展为间质性肺疾病（ILD），其特征是肺部出现炎症和进行性瘢痕形成，可导致呼吸衰竭。尽管ILD仍然是这些患者的主要死亡原因，但关于系统性硬化症相关间质性肺疾病（SSc-ILD）的分类和特征尚无共识声明。最近的临床试验探讨了SSc-ILD的治疗方法，其结果可能会带来改变疾病的新疗法。在本综述中，我们提供了SSc-ILD诊断、管理和治疗方面的最新情况。
